Communiqués Mineralys Therapeutics, Inc.

Actions

MLYS

US6031701013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
28,20 ^USD	-3,75%		-0,04%	-22,29%

12/08	Transcript : Mineralys Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026
11/08	Mineralys Therapeutics : creusement de la perte nette au deuxième trimestre	MT

Communiqués

09/09	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
26/08	Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference	AQ
13/08	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	AQ
11/08	Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
04/08	Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026	AQ
27/07	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
14/06	Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)	AQ
08/06	Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	AQ
08/06	Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)	AQ
03/06	Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock	AQ
03/06	Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing	AQ
30/05	Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)	AQ
27/05	Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference	AQ
18/05	Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)	AQ
07/05	Mineralys Therapeutics : Corporate Overview May 2026	PU
06/05	Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
05/05	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/05	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference	AQ
29/04	Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026	AQ
24/03	Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer	AQ
17/03	Mineralys Therapeutics : Corporate Overview March 2026	PU
16/03	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/03	Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update	AQ
09/03	Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results	AQ
09/03	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026	AQ